HDAC inhibitors in HIV
- PMID: 22083528
- DOI: 10.1038/icb.2011.95
HDAC inhibitors in HIV
Abstract
Combination antiretroviral therapy (cART) has led to a very substantial reduction in morbidity and mortality in HIV-infected patients; however, cART alone is unable to cure HIV and therapy is lifelong. Therefore, a new strategy to cure HIV is urgently needed. There is now a concerted effort from scientists, clinicians and funding agencies to identify ways to achieve either a functional cure (long-term control of HIV in the absence of cART) or a sterilizing cure (elimination of all HIV-infected cells). Multiple strategies aiming at achieving a cure for HIV are currently being investigated, including both pharmacotherapy and gene therapy. In this review, we will review the rationale as well as in vitro and clinical trial data that support the role of histone deacetylase inhibitors as one approach to cure HIV.
Similar articles
-
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.J Virol. 2015 Oct;89(20):10176-89. doi: 10.1128/JVI.01484-15. Epub 2015 Jul 29. J Virol. 2015. PMID: 26223643 Free PMC article. Clinical Trial.
-
In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7. Retrovirology. 2016. PMID: 27206407 Free PMC article.
-
Finding a cure for HIV: will it ever be achievable?J Int AIDS Soc. 2011 Jan 24;14:4. doi: 10.1186/1758-2652-14-4. J Int AIDS Soc. 2011. PMID: 21255462 Free PMC article.
-
The role of latency reversal agents in the cure of HIV: A review of current data.Immunol Lett. 2018 Apr;196:135-139. doi: 10.1016/j.imlet.2018.02.004. Epub 2018 Feb 7. Immunol Lett. 2018. PMID: 29427743 Review.
-
HIV cure and eradication: how will we get from the laboratory to effective clinical trials?AIDS. 2011 Apr 24;25(7):885-97. doi: 10.1097/QAD.0b013e3283467041. AIDS. 2011. PMID: 21422987 Review.
Cited by
-
Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers.PLoS Pathog. 2016 Sep 15;12(9):e1005879. doi: 10.1371/journal.ppat.1005879. eCollection 2016 Sep. PLoS Pathog. 2016. PMID: 27632364 Free PMC article.
-
Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA.PLoS Pathog. 2014 Mar 20;10(3):e1003997. doi: 10.1371/journal.ppat.1003997. eCollection 2014 Mar. PLoS Pathog. 2014. PMID: 24651404 Free PMC article.
-
Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium.Retrovirology. 2013 Nov 13;10:134. doi: 10.1186/1742-4690-10-134. Retrovirology. 2013. PMID: 24224983 Free PMC article. Review.
-
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.PLoS Pathog. 2015 Sep 17;11(9):e1005142. doi: 10.1371/journal.ppat.1005142. eCollection 2015 Sep. PLoS Pathog. 2015. PMID: 26379282 Free PMC article. Clinical Trial.
-
Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation.Curr Opin Chem Biol. 2016 Aug;33:160-8. doi: 10.1016/j.cbpa.2016.06.019. Epub 2016 Jun 29. Curr Opin Chem Biol. 2016. PMID: 27371876 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical